Lundbeck announces last patient randomized in DEEp SEA, a Phase III trial of bexicaserin in Dravet syndrome

Phase 3bexicaserinPositive

AI Analysis

Summary

Lundbeck announced the completion of patient randomization in DEEp SEA, a global Phase III trial evaluating bexicaserin for Dravet syndrome in children and adults. This milestone marks progress in the DEEp Phase III program.

Clinical Trial Data

Phase

Phase III

Outcome Details

Last patient randomized in DEEp SEA Phase III trial

Importance:5/10

Sentiment:

0.30

Phase 3clinical trialmilestoneDravet syndromebexicaserinrandomization

Related Companies

$HLUYY

Read the original article

Published by PR Newswire Biotech on September 15, 2026 7:26 AM

Read Original